Literature DB >> 516777

Cimetidine treatment of acute and chronic Zollinger-Ellison syndrome.

S Bonfils, M Mignon, J Gratton.   

Abstract

Thirteen patients with Zollinger-Ellison syndrome (ZES) were treated with cimetidine. This population could be divided into chronic forms, mostly presenting as a common duodenal ulcer, and acute forms resulting in critical problems requiring intensive medical care. Among the 7 patients with chronic ZES, cimetidine treatment was unsuccessful in 2; satisfactory clinical control was obtained in 3 others, but gastrinoma excision was the final treatment; cimetidine treatment has been prolonged for more than 15 months in the last 2 patients. If, in this condition, acute pharmacologic secretory inhibition were constantly obtained, therapeutic efficiency criteria are not sensitive enough to establish certainty in the patient's long-term follow-up. Total gastrectomy is still a valuable alternative if excision of the gastrinoma is not possible. Of the 6 patients with acute ZES, 4 were treated by pirenzepin (0.5 mg/kg intramuscularly 3 times a day) adjunctive to cimetidine infusion (2.4 mg/day), which resulted in increased antisecretory activity. However, total gastrectomy was the final outcome in every patient, with 1 immediate postoperative death. In conclusion, cimetidine in ZES treatment, although capable of inducing ulcer healing, diarrhea disappearance, and dramatic secretory inhibition, is still challenged by surgery, which allows either complete cure of the gastrinoma or definitive suppression of the secretory virulence.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 516777     DOI: 10.1007/bf01654767

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  7 in total

1.  [Efficacy of combined anti-secretory treatment (cimétidine and pirenzepin) in Zollinger-Ellison syndrome].

Authors:  S Bonfils; M Mignon; O Danne; J Maria
Journal:  Nouv Presse Med       Date:  1977-11-12

2.  H2-Histamine receptor blocking agents in the Zollinger-Ellison syndrome. Experience in seven cases and implications for long-term therapy.

Authors:  D M McCarthy; E J Olinger; R J May; B W Long; J D Gardner
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

Review 3.  Surgical management of the Zollinger-Ellison syndrome.

Authors:  P S Fox; J W Hofmann; S D Wilson; J J DeCosse
Journal:  Surg Clin North Am       Date:  1974-04       Impact factor: 2.741

4.  Duodenal wall tumors and the Zollinger-Ellison syndrome. Surgical management.

Authors:  J W Hofmann; P S Fox; S D Wilson
Journal:  Arch Surg       Date:  1973-08

5.  [Letter: Inhibitor of H 2 histamine receptors and the Zollinger-Ellison syndrome].

Authors:  S Bonfils; M Mignon; J P Accary
Journal:  Nouv Presse Med       Date:  1974-09-14

6.  Report on the United States experience with cimetidine in Zollinger-Ellision syndrome and other hypersecretory states.

Authors:  D M McCarthy
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

7.  Metiamide treatment in five patients with Zollinger-Ellison syndrome.

Authors:  S Bonfils; J J Bernier; M Mignon; R Lambert; P Bernades; C L'Hirondel; J P Accary; G Kloeti
Journal:  Digestion       Date:  1977       Impact factor: 3.216

  7 in total
  15 in total

1.  Ranitidine and cimetidine in Zollinger-Ellison syndrome.

Authors:  M Mignon; T Vallot; S Mayeur; S Bonfils
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

2.  Current approach to the management of tumoral process in patients with gastrinoma.

Authors:  M Mignon; P Ruszniewski; S Haffar; D Rigaud; E Rene; S Bonfils
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

3.  Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome.

Authors:  R T Jensen
Journal:  Dig Dis Sci       Date:  1984-04       Impact factor: 3.199

4.  Evaluation of antisecretory drug therapy of Zollinger-Ellison syndrome (ZES) using 24-hour pH monitoring.

Authors:  T Vallot; M Mignon; R Mazure; S Bonfils
Journal:  Dig Dis Sci       Date:  1983-07       Impact factor: 3.199

5.  Repeated vomiting of gastric juice in a patient with Zollinger-Ellison syndrome. Modifying influence upon clinical features.

Authors:  M Mignon; A Bonnefond; J Gratton; S Bonfils
Journal:  Dig Dis Sci       Date:  1981-08       Impact factor: 3.199

Review 6.  Use of omeprazole in patients with Zollinger-Ellison syndrome.

Authors:  H Frucht; P N Maton; R T Jensen
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

7.  The role of surgery in the Zollinger-Ellison syndrome.

Authors:  J C Thompson; B G Lewis; I Wiener; C M Townsend
Journal:  Ann Surg       Date:  1983-05       Impact factor: 12.969

8.  Outcome of lymph node involvement in patients with the Zollinger-Ellison syndrome.

Authors:  R Delcore; L Y Cheung; S R Friesen
Journal:  Ann Surg       Date:  1988-09       Impact factor: 12.969

Review 9.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

Review 10.  Current diagnosis and management of Zollinger-Ellison syndrome.

Authors:  D K Andersen
Journal:  Ann Surg       Date:  1989-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.